Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2021 Results Conference Call August 5, 2021 9:00 AM ET Company Participants Kristen Sheppard - SVP, IR John Butler - CEO David Spellman - CFO Dr. Steven Burke - Chief Medical Officer Dell Faulkingham - Chief Commercial Officer Conference Call Participants Ally Bratzel - Piper Sandler Bert Hazlett - BTIG Eric Joseph - JP Morgan Ed Arce - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to Akebia Therapeutics Second Quarter of 2021 Financial Resul ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2021 Earnings Conference Call May 10, 2021 9:00 AM ET Company Participants Kristen Sheppard - Senior Vice President, Investor Relations John Butler - Chief Executive Officer David Spellman - Chief Financial Officer Conference Call Participants Ally Bratzel - Piper Sandler Alethia Young - Cantor Fitzgerald Difei Yang - Mizuho Securities Bert Hazlett - BTIG David Lebovitz - Morgan Stanley Ed Arce - H.C. Wainwright Operator Good day, ladies and gentlemen and welcome t ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2020 Earnings Conference Call February 25, 2021 9:00 AM ET Company Participants Kristen Sheppard - VP, IR John Butler - CEO, President & Director David Spellman - SVP, CFO & Treasurer Conference Call Participants Christopher Raymond - Piper Sandler & Co. Difei Yang - Mizuho Securities Antonio Arce - H.C. Wainwright & Co. David Lebowitz - Morgan Stanley Eric Joseph - JPMorgan Chase & Co. Operator Ladies and gentlemen, thank you for standing by, and welcome to Akebia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-8756903 (State or other jurisdiction of incorporation or organizatio ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2020 Earnings Conference Call November 5, 2020 9:00 AM ET Company Participants Kristen Sheppard - Senior Vice President of Investor Relations John Butler - President and Chief Executive Officer Dave Spellman - Chief Financial Officer Conference Call Participants Ally Bratzel - Piper Sandler Alex Bouilloux - Mizuho Thomas Yip - H.C. Wainwright Bert Hazlett - BTIG Gil Blum - Needham & Company Victor Ma - RBC Capital Markets Operator Good morning, ladies and gentlemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |-- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-8756903 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ | --- | --- | |--------------------------------------------------------------------------------------------|--------------------------- ...